Focal Interest
Focal Interest
AI Summary of Peer-Reviewed Research

This page presents an AI-generated summary of a published research paper. The original authors did not write or review this article. [See full disclosure ↓]

Publishing process signals: MODERATE — reflects the venue and review process. — venue and review process.

Daraxonrasib showed antitumor activity in advanced RAS-mutated pancreatic cancer

Medicine research
Photo by Anna Tarazevich on Pexels
Research area:OncologyPancreatic and Hepatic Oncology ResearchCancer

What the study found

Daraxonrasib showed antitumor activity in previously treated advanced pancreatic ductal adenocarcinoma (PDAC, a type of pancreatic cancer) with RAS mutations. Responses were reported across KRAS G12, G13, and Q61 mutations.

Why the authors say this matters

The authors conclude that daraxonrasib has antitumor activity in previously treated advanced RAS-mutated PDAC. They also indicate that the findings are relevant because PDAC has RAS mutations in more than 90% of tumors.

What the researchers tested

The researchers studied daraxonrasib (RMC-6236), an oral RAS(ON) multiselective inhibitor, in previously treated advanced RAS-mutated PDAC. The abstract reports results in patients with KRAS G12, G13, or Q61 mutations.

What worked and what didn't

Among patients with KRAS G12, G13, or Q61 mutations, 29% had an objective response, with a 95% confidence interval of 15 to 46. The median duration of response was 8.2 months, median progression-free survival was 8.1 months, and median overall survival was 15.6 months.

What to keep in mind

The available summary does not describe the full study design, sample size, comparison group, or safety results. The results are limited to the information provided in the abstract and to previously treated advanced RAS-mutated PDAC.

Key points

  • Daraxonrasib showed antitumor activity in previously treated advanced RAS-mutated PDAC.
  • The abstract reports responses in patients with KRAS G12, G13, and Q61 mutations.
  • The objective response rate was 29% (95% CI, 15 to 46).
  • Median duration of response was 8.2 months, with median progression-free survival of 8.1 months and overall survival of 15.6 months.
  • The abstract says PDAC has RAS mutations in more than 90% of tumors.

Disclosure

Research title:
Daraxonrasib showed antitumor activity in advanced RAS-mutated pancreatic cancer
Image credit:
Photo by Anna Tarazevich on Pexels
AI provenance: AI provenance information is not available for this post.

More posts